Navigation Links
Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology

0.4% of Europeans agreed with the statement. Nearly 74% of U.S. and 44% of European physicians believed that intranasal antifungals were appropriate for surgery refractory adult CS patients. Half of U.S. and one-quarter of European respondents prescribed intranasal antifungals, and of those who did so, nearly 50% used Amphotericin B.

The third poster, entitled "Differences in Treatment Practices of Chronic Sinusitis in Europe and U.S." by Casciano, et al., provided results showing that the majority of respondents reported that almost all of their patients get some pharmacotherapy, with most of those being treated with at least two agents. Half of U.S. and one-quarter of European respondents reported prescribing intranasal antifungals, with German physicians being more likely to do so than French or British respondents. Respondents mentioned they are looking for more options to treat surgery refractory CS patients and believe pharmacotherapies are a key treatment for this patient population. Overall, the most important attributes considered by physicians when selecting CS treatment are the product's efficacy for treating surgery refractory CS and low occurrence of side-effects.

Dr. Angelos Stergiou, Medical Director at Accentia Biopharmaceuticals, commented, "With few options for the millions suffering from surgery refractory chronic sinusitis, we are excited about the potential for intranasal antifungals to provide safe and effective relief. The growing acceptance of the fungal etiology of chronic sinusitis in these patients by the medical community represents a significant advance in the treatment of this burdensome condition. We are currently in a Phase 3 clinical trial for SinuNase(TM), which we expect will provide insight into the potential of the product to become the first approved treatment for chronic sinusitis. This is a serious and debilitating disease and we hope to effectively treat those patients in need."

Dr. Raymond Slavin, from t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
(Date:5/4/2015)... LOS ANGELES , May 4, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... phase 1b aldoxorubicin combination studies pairing aldoxorubicin with ... doses of gemcitabine or ifosfamide with escalating doses ... tolerated, and even at the lowest dose level ...
(Date:5/4/2015)... , May 4, 2015 Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for quarter ending March ... 14, 2015 and will host a conference call ...
(Date:5/4/2015)... , May 4, 2015  Verus Healthcare, Inc. ... acquisition of CPAP Care Club in 2012.  Since that ... within the durable medical equipment (DME) industry by 1,000%.  ... for their CPAP supply needs and processes nearly 14,000 ... this company three years ago, the systems and processes ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2
(Date:5/4/2015)... 04, 2015 Each year, the Susan G. ... funds and awareness for breast cancer. This year, Dr. Mark ... featured as the entertainment sponsor for the 25th annual Susan ... 9 at the Lenox Square Mall. , The Komen organization ... to raise $1.2 million. Perimeter Plastic Surgery has not only ...
(Date:5/4/2015)... 04, 2015 Johnson & Wales University (JWU) ... and science academic center on Wednesday, April 22. , Johnson ... land made available by the re-alignment of Interstate-195. JWU’s new ... Friendship and Chestnut streets in Providence, is scheduled to be ... parcel of land the university purchased in 2012. , “It ...
(Date:5/4/2015)... 2015 The Lymphoma Research Foundation (LRF) ... funding innovative lymphoma research and serving the lymphoma community ... and patient services – is set to host its ... in West Orange, NJ on June 1, 2015. Since ... research programs through LRF. , This year, the Lymphoma ...
(Date:5/4/2015)... Fla. (PRWEB) May 04, 2015 ... Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke ... Target: Stroke Honor Roll. The award recognizes the ... patients receive the most appropriate treatment according to ... scientific evidence. , To receive the Gold Plus ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis is expected ... senior citizens (1) and 27 million Obamacare-insured Americans (2) ... Additionally, as older healthcare employees retire, there will be ... Census Bureau, the number of American workers 65 and ... those 25 to 54 will likely increase 2%. (3) ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... 10 Charlotte,s VR Mergers and,Acquisitions has just ... fixture in Laurinburg, NC. VR Charlotte links business ... the transaction were,not disclosed., Established in 1965, ... there since it opened. Todd, the owner since ...
... AURORA, Ohio, Dec. 10 PartsSource, the nation,s ... equipment has,been recognized as a 2007 Pillar Award ... to companies that have distinguished themselves,through leading by ... others., "My initial vision for PartsSource was ...
... (Dec. 10, 2007) Climate change will affect national ... world, in some cases altering conditions so severely that ... planet, according to a study presented at the U.N. ... International (CI), the University of Wisconsin and the University ...
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... (Amex: ANX ), a biopharmaceutical research and ... the treatment,of cancer and infectious diseases, announced today ... scheduled to present at the 2007 RBC,Capital Markets ... Better Drugs &,Novel Approaches To Cancer Therapy on ...
... Resources Professional Brings Diverse Expertise, MIAMI, Dec. ... products to healthcare providers, is pleased,to announce that ... President of,Human Resources. Ms. Lopez was most recently ... Johnson Company. Her 17-year career began,in Human Resources ...
Cached Medicine News:Health News:New study shows world's protected areas threatened by climate change 2Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Medicine Products: